Journal of Pain and Symptom Management
Volume 17, Issue 5 , Pages 384-386 , May 1999

Clinical Experience with Oral Ketamine

  • Mark C Enarson, BSc

      Affiliations

    • Department of Family Medicine, University of Alberta, Edmonton, Alberta, Canada
    • ,
  • Helen Hays, MD

      Affiliations

    • Department of Family Medicine, University of Alberta, Edmonton, Alberta, Canada
    • Corresponding Author InformationHelen Hays, MD, 604 College Plaza, Edmonton, Alberta, Canada T6G 2C8
    • ,
  • Mary Ann Woodroffe

      Affiliations

    • Department of Family Medicine, University of Alberta, Edmonton, Alberta, Canada
    • ,
  • Bscn

      Affiliations

    • Department of Family Medicine, University of Alberta, Edmonton, Alberta, Canada

,Accepted 31 August 1998.

References 

  1. Lodge D, Johnson KM. Noncompetitive excitatory amino acid receptor antagonists. Trends Pharmacol Sci. 1990;11:81–86
  2. US Pharmacopoeia Dispensing Information . Ketamine—systemic. Rockville: Rand McNally; 1993;
  3. Backonja M, Arndt G, Gombar KA, Check B, Zimmermann M. Response of chronic neuropathic pain syndromes to ketamine (a preliminary study). Pain. 1994;56:51–57
  4. Mathisen LC, Skjelbred P, Skoglund LA, Oye I. Effect of ketamine, an NMDA receptor inhibitor, in acute and chronic orofacial pain. Pain. 1995;61:215–220
  5. Eide PK, Jorum E, Stubhaug A, Bremnes J, Brevik H. Relief of post-herpetic neuralgia with the N-methyl-D-aspartic acid receptor antagonist ketamine (a double-blind, cross-over comparison with morphine and placebo). Pain. 1994;58:347–354
  6. Eide PK, Stubhaug A, Oye I, Breivik H. Continuous subcutaneous administration of the N-methyl-D-aspartic acid (NMDA) receptor antagonist ketamine in the treatment of post-herpetic neuralgia. Pain. 1995;61:221–228
  7. Felsby S, Nielsen J, Arendt-Nielsen L, Jensen TS. NMDA receptor blockade in chronic neuropathic pain (a comparison of ketamine and magnesium chloride). Pain. 1995;64:283–291
  8. Nikolajsen L, Hansen CL, Nielsen J, Keller J, Arendt-Nielsen L, Jensen TS. The effect of ketamine on phantom pain (a central neuropathic disorder maintained by peripheral input). Pain. 1996;67:69–77
  9. Rabben T, Oye I. Long-term inhibition of neuropathic orofacial pain by ketamine, an NMDA receptor inhibitor (Abst). In: Eighth World Congress on Pain. Seattle: IASP Press, 1996:154.
  10. White T, Way WL, Trevor AJ. Ketamine—its pharmacology and therapeutic uses. Anesthesiology. 1982;56:119–136
  11. Stannard CF, Porter GE. Ketamine hydrochloride in the treatment of phantom limb pain. Pain. 1993;54:227–230
  12. Jensen MP, Karoly P. Motivation and expectancy factors in symptom perception (a laboratory study of the placebo effect). Psychosom Med. 1991;53:144–152
  13. Reich DL, Silvay G. Ketamine (an update on the first twenty-five years of clinical experience). Can J Anaesth. 1989;36:186–197
  14. Meller ST. Ketamine (relief from chronic pain through actions at the NMDA receptor? (Letter)). Pain. 1996;68:435–436
  15. Craig KD. Emotional aspects of pain. In:  Wall PD,  Melzack RA editor. Textbook of pain. 2nd ed. Edinburgh: Churchill Livingstone; 1989;p. 220–230
  16. Hagen N, Flynne P, Hays H, MacDonald N. Guidelines for managing chronic non-malignant pain. Can Fam Physician. 1995;41:49–53
  17. Hansson P. Neurogenic pain (diagnosis and treatment). IASP Pain Clinical Updates. Seattle: IASP Press. 1994;2:1–4

PII: S0885-3924(99)00011-1

Journal of Pain and Symptom Management
Volume 17, Issue 5 , Pages 384-386 , May 1999

Article Tools